Novavax, Inc. filed a Form 8-K on October 29, 2026, disclosing that a patient-dosing milestone in Sanofi's Phase 3 influenza-COVID-19 combination vaccine trial triggered a $125 million payment obligation from Sanofi under their existing Collaboration and License Agreement.

Key Highlights

  • Fifth patient dosed: Sanofi Pasteur Inc. dosed the fifth patient in its Phase 3 influenza-COVID-19 combination vaccine trial in the European Union on October 28, 2026, using Novavax's COVID-19 component.
  • $125 million milestone triggered: The dosing of the fifth patient triggered a $125 million milestone payment from Sanofi under the Collaboration and License Agreement.
  • Expected payment timing: According to the filing, Novavax anticipates receipt of the payment by the first quarter of 2027.
  • Combination vaccine trial: The trial is described as a Phase 3 influenza-COVID-19 combination vaccine trial conducted in the European Union.
  • Press release issued: Novavax issued a press release on October 29, 2026, announcing the milestone event, furnished as Exhibit 99.1 to the filing.

Sanofi Phase 3 Trial Milestone Triggers Payment Under Novavax Collaboration Agreement

According to the Form 8-K filed with the SEC by Novavax, Inc. (NASDAQ:NVAX) on October 29, 2026, Sanofi Pasteur Inc. dosed the fifth patient in its Phase 3 influenza-COVID-19 combination vaccine trial in the European Union on October 28, 2026. The trial utilizes Novavax's COVID-19 component, and the filing states that reaching this dosing milestone has "triggered a $125 million milestone payment from Sanofi under the Company's Collaboration and License Agreement with Sanofi."

The filing further states that "the Company anticipates receipt of payment by the first quarter of 2027." The disclosure was made under Item 8.01 (Other Events) of the Form 8-K, with a corresponding press release, dated October 29, 2026, furnished as Exhibit 99.1. The filing was signed by Mark J. Casey, Executive Vice President, Chief Legal Officer and Corporate Secretary of Novavax.

The filing includes forward-looking statements, specifically regarding expected milestone payments under the Sanofi agreement. Novavax noted that such statements are subject to risks and uncertainties, including "challenges related to Novavax's partnership with Sanofi," manufacturing and distribution challenges, regulatory risks, and other factors detailed in its Annual Report on Form 10-K for the year ended December 31, 2025, filed February 26, 2026, and subsequent quarterly filings. The company stated it undertakes no obligation to update forward-looking statements unless required by law.

What Was Disclosed

Novavax disclosed via an 8-K that a patient-dosing event in Sanofi's European Phase 3 combination vaccine trial triggered a $125 million contractual milestone payment, with receipt anticipated in the first quarter of 2027.